Skip to main content
SpringerLink
Log in

Pharmacokinetic and pharmacodynamic data and models in clinical trials

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

There is current emphasis for extended integration of pharmacokinetics (PK) and pharmacodynamics (PD) into all phases of new drug development, including large-scale clinical trials. In this paper, we focus on study design and data analysis issues for the investigation of pharmacokinetic/pharmacodynamic and blood level/effect relationships in patients. The application of descriptive and model-based regression statistical methodology for including sparse drug systemic concentration data in the analysis of efficacy and safety is illustrated by examples chosen from diverse therapeutic areas. The population approach, based on mixed-effects modelling, is one such methodology, which also provides new tools for analysis of response vs dose and response vs time data. The existence of a variety of statistical techniques for handling complex PK/PD time-varying data should increase the impact of such data analysis on future drug development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balant L.-P., Roseboom H., Gundert-Remy U.M. (1990): Pharmacokinetic criteria for drug research and development. Adv. Drug Res., 19, 1–138.

    CAS  Google Scholar 

  2. Salmonson T., Rane A. (1990): Clinical pharmacokinetics in the drug regulatory process. Clin. Pharmacokinet., 18, 177–183.

    Article  PubMed  CAS  Google Scholar 

  3. Sheiner L.B., Stanski D.R., Vozeh S., Miller R.D., Ham J. (1979): Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther., 25(3), 358–371.

    PubMed  CAS  Google Scholar 

  4. van Boxtel C.J., Holford N.H.G., Danhof M., eds. (1992): The in vivo study of drug action: Principles and applications of kinetic-dynamic modelling. Amsterdam, Elsevier.

    Google Scholar 

  5. Verotta D., Beal S.L., Sheiner L.B. (1989): Semiparametric approach to pharmacokinetic-pharmacodynamic data. Am. J. Physiol., 256, (Regul. Integ. Comp. Physiol. 25) R1005-R1010.

    PubMed  CAS  Google Scholar 

  6. Verotta D., Sheiner L.B. (1991): Semiparametric analysis of non steady-state pharmacodynamic data. J. Pharmacokinet. Biopharm., 19, 691–712.

    Article  PubMed  CAS  Google Scholar 

  7. Veng-Pedersen P., Mandema J.W., Danhof M. (1991): A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. J. Pharm. Sci., 80(5), 488–495.

    Article  PubMed  CAS  Google Scholar 

  8. Beal S.L., Sheiner L.B., eds. (1992): NONMEM Users Guides, Version IV. NONMEM Project Group, San Francisco, University of California at San Francisco.

    Google Scholar 

  9. Sheiner L.B., Rosenberg B., Melmon K.L. (1972): Modeling of individual pharmacokinetics for computer-aided drug dosage. Comp. Biomed. Res., 5, 441–459.

    Article  Google Scholar 

  10. Weiner D.L. (1986): NONLIN84/PCNONLIN: Software for the statistical analysis of nonlinear models. Methods Find. Exp. Clin. Pharmacol., 8, 625–628.

    PubMed  CAS  Google Scholar 

  11. Berman M., Beltz W.F., Greif P.C., Chabay R., Boston R.C. (1983): CONSAM user’s guide. National Cancer Institute, NIH, Bethesda, Maryland, USA.

    Google Scholar 

  12. Steiner E.C., Rey T.D., McCroskey D.S. (1990): SimuSolv: Modeling and simulation software. The Dow Chemical Company, Midland, Michigan 48674, USA.

    Google Scholar 

  13. Fuseau E., Sheiner L.B. (1984): Simultaneous modelling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin. Pharmacol. Ther., 35, 733–741.

    Article  PubMed  CAS  Google Scholar 

  14. Kroboth P.D., Smith R.B., Juhl R.P., eds. (1988): Pharmacokinetics and pharmacodynamics: Current problems, potential solutions. Cincinnati, Harvey Whitney Books.

    Google Scholar 

  15. Mallet A. (1986): A maximum likelihood estimation method for random coefficient regression models. Biometrika, 73, 645–656.

    Article  Google Scholar 

  16. Hashimoto Y., Sheiner L.B. (1991): Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J. Pharmacokinet. Biopharm., 19, 333–353.

    Article  PubMed  CAS  Google Scholar 

  17. Sheiner L.B., Beal S.L., Sambol N.C. (1989): Study designs for dose-ranging. Clin. Pharmacol. Ther., 46, 63–77.

    Article  PubMed  CAS  Google Scholar 

  18. Sheiner L.B., Hashimoto Y., Beal S.L. (1991): A simulation study comparing designs for dose ranging. Stat. Med., 10, 303–321.

    Article  PubMed  CAS  Google Scholar 

  19. Rowland M., Sheiner L.B., Steimer J.L., eds. (1985): Variability in Drug Therapy: Description, Estimation and Control. New York, Raven Press.

    Google Scholar 

  20. Temple R. (1983): Discussion paper on the testing of drugs in the elderly. Memorandum of the Food and Drug Administration (September 30), Washington DC, DHHS.

    Google Scholar 

  21. Temple R. (1987): The clinical investigation of drug use by the elderly: Food and Drug guidelines. Clin. Pharmacol. Ther., 42, 681–685.

    Article  PubMed  CAS  Google Scholar 

  22. Koch-Weser J., Klein W. (1971): Procainamide dosage schedules, plasma concentrations and effects. JAMA, 215, 1454–1460.

    Article  PubMed  CAS  Google Scholar 

  23. Kroboth P.D., Schmith V.D., Smith R.B. (1991): Pharmacodynamic modeling: Application to new drug development. Clin. Pharmacokinet., 20, 91–98.

    Article  PubMed  CAS  Google Scholar 

  24. Campbell D.B. (1990): The use of kinetic-dynamic interactions in the evaluation of drugs. Psychopharmacology, 100, 43–450.

    Article  Google Scholar 

  25. Sale M.E., Blaschke T.F. (1992): Ineorporating pharmacokinetic/pharmacodynamic modeling in drug development — Are we ready? Drug Inf. J., 26, 119–124.

    Google Scholar 

  26. Peck C.C. (1992): Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: Rowland M., Asrons L., eds. New strategies in Drug Development and Clinical Evaluation: The population approach. Luxembourg, Commission of the European Communities, pp 157–168.

    Google Scholar 

  27. Peck C.C., Barr W.H., Benet L.Z., et al. (1992): Conference Report: Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther., 51, 465–473.

    Article  PubMed  CAS  Google Scholar 

  28. Holford N.H.G., Peck C.C. (1992): Population pharmacodynamics and drug development. In: van Boxtel C.J., Holford N.H.G., Danhof M. eds. The in vivo study of drug action: Principles and applications of kinetic-dynamic modelling. Elsevier, Amsterdam.

    Google Scholar 

  29. Sheiner L.B. (1992): Population approach in drug development: rationale and basic concepts. In: Rowland M., Aarons L. eds. New strategies in Drug Development and Clinical Evaluation: The population approach. Luxembourg, Commission of the European Communities, pp 13–29.

    Google Scholar 

  30. Steimer J.L., Vozeh S., Racine-Poon A., Holford N., O’Neill R. (1993): The population approach: rationale, methods, applications in clinical pharmacology and drug development. In: Welling P.E., Balant L.P., eds. Pharmacokinetics of Drugs. Handbook of Experimental Pharmacology. Heidelberg, Springer-Verlag. (In press)

  31. Danhof M. (1993): Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Eur. J. Drug Metab. Pharmacokinet. (this issue).

  32. van Peer A. (1993): Pharmacokinetic-pharmacodynamic relationships in Phase I/Phase II of drug development. Eur. J. Drug Metab. Pharmacokinet. (this issue).

  33. Mandema J.W., Sansom L.N., Dios-Vieitez M.C., Hollander-Jansen M., Danhof M. (1991): Pharmacokinetic-pharmacodynamic modelling of the EEG effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Pharmacol. Exp. Ther., 257, 472–478.

    PubMed  CAS  Google Scholar 

  34. Williams R.L. (1992): Dosage Regimen Design: Pharmacodynamic Considerations. J. Clin. Pharmacol. 32, 597–602.

    PubMed  CAS  Google Scholar 

  35. Steimer J.L., Mentre F., Mallet A. (1984): Population studies for evaluation of pharmacokinetic variability: Why? How? When?. In: Aiache J.M., Hirtz J., eds. 2nd European Congress on Biopharmaceutics and Pharmacokinetics, vol. 2: Experimental Pharmacokinetics. Paris, Editions Lavoisier, pp 40–49.

    Google Scholar 

  36. Sheiner L.B., Benet L.Z. (1985): Premarketing observational studies of population pharmacokinetics of new drugs. Clin. Pharmacol. Ther., 38, 481–487.

    Article  PubMed  CAS  Google Scholar 

  37. Hundt H.K.L., Aucamp A.K., Mueller F.O., Potgieter M.A. (1983): Carbamazepine and its major metabolites in plasma: A summary of eight years of therapeutic drug monitoring. Ther. Drug Monit., 5, 427–435.

    Article  PubMed  CAS  Google Scholar 

  38. Mallet A., Mentre F. (1988): An approach to the design of experiments for estimating the distribution of parameters in random models. In: Vichnevetsky R., Borne P., Vignes J., eds. Proc. 12th IMACS World Congress 5, pp 134–137

  39. Food and Drug Administration. (1989): Guideline for the study of drugs likely to be used in the elderly. Centre for Drug Evaluation and Research, Food and Drug Administration. Washington DC, DHHS.

    Google Scholar 

  40. Feutren G., Friend D., Timonen P., Barnes A., Laburte C. (1990): Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis. Br. J. Dermatol., 122, Suppl 36, 85–93.

    Article  PubMed  Google Scholar 

  41. Eagger S., Levy R. (1992): Serum levels of tacrine in relation to clinical response in Alzheimer’s disease. Int. J. Geriatr. Pay., 7, 115–119.

    Article  Google Scholar 

  42. Antal E.J., Pyne D.A., Starz K.E., Smith R.B. (1988): Probability models in pharmacodynamic analysis of clinical trials. In: Kroboth P.D., Smith R.B., Juhl R.P. eds. Pharmacokinetics and pharmacodynamics: Current problems, potential solutions, vol. 2. Cincinnati, Harvey Whitney Books, pp 220–231.

    Google Scholar 

  43. Cox D.R. (1972): Regression models and life tables (with discussion). J. R. Stat. Soc. B, 34, 187–220.

    Google Scholar 

  44. Yee G.C., Kennedy M.S., Gmur D.J., et al. (1986): Pharmacodynamics of cyclosporine in patients undergoing bone marrow transplantation. Transplant Proc., 18, 774–775.

    Google Scholar 

  45. Yee G.C., Self S.G. (1988): Application of relative risk regression models to pharmacodynamic studies. In: Kroboth P.D., Smith R.B., Juhl R.P. eds. Pharmacokinetics and pharmacodynamics: Current problems, potential solutions, vol. 2. Cincinnati, Harvey Whitney Books, pp 206–218.

    Google Scholar 

  46. Grevel J., Welsh M.S., Kahan B.D. (1989): Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough level monitoring. Ther. Drug Monit., 11, 246–248.

    Article  PubMed  CAS  Google Scholar 

  47. Grevel J., Napoli K.L., Welsh M.S., Atkinson N.E., Kahan B.D. (1991): Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations. Pharmacol. Res., 8(2), 278–281.

    Article  CAS  Google Scholar 

  48. Sanathanan L., Peck C. (1991): Pharmacodynamic measures based on CD4 lymphocyte counts for assessing the effect of anti-HIV therapy. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 207–222.

    Google Scholar 

  49. Ratain M.J., Schilsky R.L., Conley B.A., Egorin M.J. (1990): Pharmacodynamics in cancer therapy. J. Clin. Oncol, 8(10), 1739–1753.

    PubMed  CAS  Google Scholar 

  50. Vozeh S., Uematsu T., Ritz R., Schmidlin O., Kaufman G., Scholer A., Follath F. (1987): Computer-assisted individualized lidocaine dosage: Clinical evaluation and comparison with physician performance. Am. Heart J., 113, 928–933.

    Article  PubMed  CAS  Google Scholar 

  51. Escolano S., Mentre F., Golmard J.L., Diquet B., Mallet A. (1991): A reduced dose of zidovudine in patients with AIDS. N. Engl J. Med., 324, 995.

    Google Scholar 

  52. Mentre F., Mallet A. (1992): Experiences with NPML — Application to dosage individualisation of cyclosporine, gentamicin and zidovudine. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 75–90.

    Google Scholar 

  53. Escolano S., Mentre F., Golmard J.L., Diquet B., Mallet A. (1991): Plasma concentrations of zidovudine. N. Engl J. Med., 326, 1571.

    Google Scholar 

  54. George S.L. (1988): Use of statistical models in assessing the relationships among pharmacokinetic variables, clinical variables, and outcome. In: Kroboth P.D., Smith R.B., Juhl R.P. eds. Pharmacokinetics and pharmacodynamics: Current problems, potential solutions, vol. 2. Cincinnati, Harvey Whitney Books, pp 186–204.

    Google Scholar 

  55. Laplanche R., Fertil B., Nüesch E., Jais J.P., Niederberger W., Steimer J.L. (1991): Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin. Pharmacol. Ther., 50, 39–54.

    Article  PubMed  CAS  Google Scholar 

  56. Niederberger W., Gonasun L.M., Kutz K., et al. (1987): A population pharmacokinetic study during phase III clinical trials for the calcium antagonist PN 200-110 (isradipine). In: Aiache J.M., Hirtz J., eds. Proc 3rd Eur. Congress Biopharm. Pharmacokinet, Vol. 3, Clinical Pharmacokinetics. Clermont-Ferrand, University of Clermont-Ferrand, pp 45–54.

    Google Scholar 

  57. Chambers J.M., Cleveland W.S., Kleiner B., Tukey P.A. (1983): Graphical methods for data analysis. Wadsworth.

  58. Ebelin M.E., Steimer J.L., Laplanche R., Niederberger W. (1992): An evaluation of population pharmacokinetics during drug development: Experiences with graphical exploratory analysis for isradipine and tropisetron. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 131–141.

    Google Scholar 

  59. Mandema J.W., Verotta D., Sheiner L.B. (1992): Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm., 20, 511–528.

    Article  PubMed  CAS  Google Scholar 

  60. Vozeh S. (1991): Applications of population approach to clinical pharmacokinetics and validation of the results. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 107–124.

    Google Scholar 

  61. Sanathanan L., Peck C.C., Temple R., Lieberman R., Pledger G. (1991): Randomization, pharmacokinetic-controlled dosing, and titration: an integrated approach for designing clinical trials. Drug Inf. J., 25, 425–431.

    Google Scholar 

  62. Sanathanan L., Peck C.C. (1991): The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Controlled Clin. Trials, 12, 780–794.

    Article  PubMed  CAS  Google Scholar 

  63. Kragh-Sorensen P., Eggert Hansen C., Baastrup P.C., Hvidberg E.F. (1976): Self-inhibiting action of nortriptylin’s anti-depressive effect at high plasma levels. Psychopharmacologia, 45, 305–312.

    Article  PubMed  CAS  Google Scholar 

  64. Vozeh S., Kewitz G., Penuchoud A., Tschan M., Kopp C., Heitz M., Follath F. (1982): Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: The optimal use of intravenously administered aminophylline. Am. Rev. Respir. Dis., 125, 181–184.

    PubMed  CAS  Google Scholar 

  65. Gelenberg A.J., Kane J.M., Keller M.B., et al. (1989): Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N. Engl. J. Med., 321, 1489–1493.

    Article  PubMed  CAS  Google Scholar 

  66. Evans W.E., Crom W.E., Abromowitch M., et al. (1986): Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. N. Engl J. Med., 314, 471–477.

    Article  PubMed  CAS  Google Scholar 

  67. Rodman J.H., Abromowitch M., Sinkule J.A., et al. (1987): Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a Phase I trial. J. Clin. Oncol., 7, 1007–1014.

    Google Scholar 

  68. Vozeh S. (1987): Cost-effectiveness of therapeutic drug monitoring. Clin. Pharmacokinet., 13, 131–140.

    Article  PubMed  CAS  Google Scholar 

  69. Rubio A., Cox C., Weintraub M. (1992): Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin. Pharmacokinet., 22(3), 238–246.

    Article  PubMed  CAS  Google Scholar 

  70. Sheiner L.B., Ludden T.M. (1992): Population pharmacokinetics/pharmacodynamics. Annu. Rev. Pharmacol. Toxicol., 32, 185–209.

    Article  PubMed  CAS  Google Scholar 

  71. Aarons L., Mandema J., Danhof M. (1991): A population analysis of the pharmacokinetics and pharmacodynamics of Midazolam in the rat. J. Pharmacokinet. Biopharm., 19, 485–496.

    Article  PubMed  CAS  Google Scholar 

  72. Aarons L. (1993): Sparse data analysis. Eur. J. Drug Metab. Pharmacokinet. (This issue)

  73. Sambol N.C., Sheiner L.B. (1991): Population dose versus response of betaxolol and atenolol: a comparison of potency and variability. Clin. Pharmacol. Ther., 49, 24–31.

    Article  PubMed  CAS  Google Scholar 

  74. Sheiner L.B. (1991): The intellectual health of clinical drug evaluation. Clin. Pharmacol. Ther., 50, 4–9.

    Article  PubMed  CAS  Google Scholar 

  75. Venot A., Mentre F., Herbin M., Siney H., Vinet L., Strauch G. (1992): Nouvelles methodes d’evaluation de la phototoxicite des antibiotiques a partir de l’analyse d’image et d’un modele de population. In: Chastang C., Pons G., Regnier B., eds. Methodes nouvelles en pharmacologie clinique pediatrique. Heidelberg, Springer Verlag

    Google Scholar 

  76. Holford N.H.G. (1992): Parametric models for the time course of drug action: the population approach. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 193–206.

    Google Scholar 

  77. Schmith V.D., Fiedler-Kelly J., Abou-Donis M., Huffmann C.S., Grasela T.H. (1992): Population pharmacodynamics of doxacurium. Clin. Pharmacol. Ther., 52, 528–536.

    Article  PubMed  CAS  Google Scholar 

  78. Balant L.P. (1993): Blood concentration measurements during clinical trials: potential advantages and some unresolved issues. Appl. Clin. Trials (In press)

  79. Vollmer K.O. et al. (1992): Practical issues in possible implementation of population pharmacokinetics in drug development (discussion). In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 169–179.

    Google Scholar 

  80. O’Neill R.T. (1992): Statistical issues in population models. In: Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities, pp 99–105.

    Google Scholar 

  81. Rowland M., Aarons L., eds. New strategies in drug development and clinical evaluation: the population approach. Luxembourg, Commission of the European Communities.

  82. Bortey E.B., Gould A.L. (1991): Applying survival methodology to adverse experience occurrences in controlled clinical trials. J. Biopharm. Stat., 1(1), 57–66.

    Article  PubMed  CAS  Google Scholar 

  83. Pollak T. (1990): The exploration of pharmacokinetic and pharmacodynamic data using interactive three-dimensional graphs, a tool borrowed from particle physics. Eur. J. Clin. Pharmacol., 39, 525–532.

    Article  PubMed  CAS  Google Scholar 

  84. Gentleman R., Crowley J. (1991): Graphical Methods for Censored Data. J. Am. Stat. Assoc., 86(415), 678–683.

    Article  Google Scholar 

  85. SAS. (1988): Statistical Analysis System (Version 6). SAS Institute, Inc., Box 8000, Cary, NC 27511

    Google Scholar 

  86. Chambers J.M., Hastie T.J., eds. (1992): Statistical models in S. Wadsworth & Brooks, Pacific Grove, CA

    Google Scholar 

  87. Veng-Pedersen P., Modi N.B. (1992): Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end? J. Pharmacokinet. Biopharm., 20, 397–412.

    Article  PubMed  CAS  Google Scholar 

  88. Siegel R. (1992): Commentary on ‘Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?’ J. Pharmacokinet. Biopharm., 20, 413–416.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacometrics, Drug Safety Assessment, Sandoz Pharma, WSP/LTG 751/306, CH-4002, Basel, Switzerland

    J. L. Steimer & M. E. Ebelin

  2. Biopharmaceutics, Drug Safety Assessment, Sandoz Pharma, WSP/LTG 751/306, CH-4002, Basel, Switzerland

    J. Van Bree

Authors
  1. J. L. Steimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. E. Ebelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Van Bree
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steimer, J.L., Ebelin, M.E. & Van Bree, J. Pharmacokinetic and pharmacodynamic data and models in clinical trials. Eur. J. Drug Metab. Pharmacokinet. 18, 61–76 (1993). https://doi.org/10.1007/BF03220009

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03220009

Keywords

Search

Navigation